期刊文献+

抗HPV16E6核酶对宫颈癌CaSKi细胞增殖和侵袭力的影响

Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi
下载PDF
导出
摘要 目的研究特异性抗HPV16E6核酶对宫颈癌CaSKi细胞增殖和侵袭能力的影响。方法以脂质体法将抗HPV16E6核酶、空载体质粒分别导入CaSKi细胞,分别为CaSKi-R和CaSKi-P。观察细胞的生长状态,测定CaSKi,CaSKi-R和CaSKi-P3种细胞的生长曲线、软琼脂克隆形成率、细胞侵袭力实验、裸鼠体内致瘤性,以及RT-PCR检测细胞中COX-2、血管内皮生长因子(VEGF)的表达,同时,免疫组化检测3种细胞COX-2、VEGF抗原表达,分析特异性抗HPV16E6核酶对宫颈癌CaSKi细胞增殖和侵袭力的影响。结果CaSKi、CaSKi-P细胞生长速率、软琼脂克隆形成率、致瘤性和侵袭力相近,而CaSKi-R细胞的细胞生长速率、软琼脂克隆形成率、致瘤性和侵袭力与以上两种细胞相比却明显降低。RT-PCR检测CaSKi-R细胞的COX-2、VEGF表达水平也低于CaSKi、CaSKi-P细胞的表达。细胞免疫组化测定CaSKi、CaSKi-P和CaSKi-R细胞都有COX-2、VEGF抗原表达,而CaSKi-R细胞的抗原染色程度较弱。结论特异性抗HPV16E6核酶的导入降低了宫颈癌CaSKi细胞的增殖和侵袭表型,可能与宫颈癌CaSKi细胞内COX-2、VEGF的表达水平降低有关。 Objective To investigate the effects of anti-HPV16-ribozyme on the cell proliferation and invasiveness of cultured cervical cancer cell line CaSKi. Methods CaSKi cells were transfected with anti-HPV16 E6-ribozyme and empty eukaryotic expression plasmids via lipofectin and designated as CaSKi-R and CaSKi-P cells respectively. The growth rate, cell colony-forming ability on soft agar, invasiveness and tumorigenicity of CaSKi-R, CaSKi-P, and CaSKi cells were studied using corresponding methods. The expressions of cox-2 and vascular endothelial growth factor (VEGF) mRNA of the 3 cell strains were determined with one-step reverse transcriptional PCR (RT-PCR), and immunocytochemistry was employed for detecting the expressions of COX-2 and VEGF antigens. Results No distinct differences in the growth rate, colony-forming ability on soft agar, cell invasiveness and tumorigenicity were observed between CaSKi and CaSKi-P cells, whereas by comparison, CaSKi-R cells exhibited decreased growth rate, colony-forming ability, the cell invasiveness and tumorgenicity, with also lowered expression levels of cox-2 and VEGF mRNA as shown by RT-PCR analysis. Expressions of COX-2 and VEGF antigens were detected in all the 3 cell strains immunocytochemically, but compared with CaSKi and CaSKi-P cells, the antigen expressions in CaSKi-R cells were significantly weaker. Conclusion Anti-HPV16 E6-ribozyme may partially inhibit the prolifera- tion and reduce the invasiveness of CaSKi cells possibly through decreasing cox-2 and VEGF expressions, which are the important agents for tumor invasion.
出处 《第一军医大学学报》 CSCD 北大核心 2004年第12期1367-1372,共6页 Journal of First Military Medical University
基金 广东省自然科学基金(96058)~~
关键词 核酶 子宫颈癌 侵袭力 环氧合酶-2 血管内皮生长因子 ribozyme cervical cancer invasiveness COX-2 vascular endothelial growth factor
  • 相关文献

参考文献4

二级参考文献13

  • 1Ausubel FM等 颜子颖 等.精编分子生物学实验指南[M].北京:科学出版社,1998.120-45. 被引量:1
  • 2He Y K,FEBS Lett,1993年,322卷,21页 被引量:1
  • 3AusubelFM BrentR KingstonRE eta1 颜子颖 王海林译.精编分子生物学实验指南[M].北京:科学出版社,1998.37. 被引量:27
  • 4Lazo PA.The molecular genetics of cervical carcinoma[J].Br J Cancer,1999,80(12): 2008-18. 被引量:1
  • 5Nevins JR.A link between the Rb tumor suppressor protein and viral oncoproteins[J].Science,1992,258(5081):424-9. 被引量:1
  • 6Lowe SW,Ruley HE,Jacks T,et al.p53-dependent apoptosis modulates the cytotoxicity ofanticancer drugs [J].Cell,1993,74(7): 957-67. 被引量:1
  • 7Zhang Z,Liu Q,Lantry LE,et al.A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin [J].Cancer Res,2000,60(4): 901-7. 被引量:1
  • 8Das GC,Holiday D,Gallardo R,et al.Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic conditions [J].Cancer Lett,2001,165(2): 147-53. 被引量:1
  • 9Segawa T,Sasagawa T,Yamazaki H,et al.Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma [J].Cancer,1999,85(9): 2001-10. 被引量:1
  • 10Umesaki N,Izumi R,Fushiki H,et al.Cervical adenocarcinoma,a novel combination chemotherapy with mitomycin C,etoposide,and cisplatin for advanced or recurrent disease [J].Gynecol Oncol,1999,75(1): 142-4. 被引量:1

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部